 BROOKLYN, N.Y., June 09, 2021 GLOBE NEWSWIRE -- Brooklyn ImmunoTherapeutics, Inc. NYSE American: BTX Brooklyn, a biopharmaceutical company focused on exploring the role that cytokine and gene editingcell therapy can have in treating patients with cancer, blood disorders, and monogenic disorders, today announced Brooklyns addition to the Russell 3000 Index. This milestone will take place at the conclusion of the 2021 Russell Indexes annual reconstitution, effective after the U.S. market opens on June 28, 2021 according to a preliminary list of additions posted June 4, 2021. 